Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals is a fundamentally sound company with a strong commercial portfolio and a focus on addressing high unmet medical needs. Its well-established drugs, HETLIOZ and Fanapt, have shown consistent revenue growth, and the company's pipeline options for schizophrenia, bipolar disorder, and MDD, as well as its legacy portfolio and cash on hand, contribute to a positive outlook for future growth. Additionally, Vanda has multiple potential regulatory catalysts approaching, including an FDA approval decision for its GPP treatment and ongoing trials for other indications. The application of a discounted cash flow analysis yields a price objective of $21 per share, which is significantly higher than the current stock price. However, risks such as slower sales traction, generic erosion, and negative pricing developments should be considered.

Bears say

Vanda Pharmaceuticals is facing several challenges that could negatively impact its stock performance. The company missed revenue expectations in the second quarter due to timing issues, and its cash balance has decreased. The company's reliance on one product, Fanapt, for the majority of its revenue also increases its vulnerability to shifts in market trends and competition. Additionally, the company faces potential commercial and financial risks related to its pipeline development, and its financial outlook for the next few years appears unfavorable.

Vanda Pharmaceuticals (VNDA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 6 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.